NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Leukemia, Lymphocytic, Chronic, B-Cell
Explore clinical trials studying Leukemia, Lymphocytic, Chronic, B-Cell. Study availability and eligibility vary by location and protocol.
1,432 public trials
166 recruiting studies
Leukemia, Lymphocytic, Chronic, B-Cell trial results
Active, Not Recruiting
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
NCT06170671
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
- Locations
-
- Research Site Piteşti, Argeş, Romania
- Research Site Oradea, Bihor County, Romania
- Research Site Cluj-Napoca, Cluj, Romania
- Research Site Craiova, Dolj, Romania
Active, Not Recruiting
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
NCT01787409
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +40 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Emory University/Winship Cancer Institute Atlanta, Georgia, United States
- University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +14 more
- Locations
-
- Research Site Beijing, China
- Research Site Changchun, China
- Research Site Changsha, China
- Research Site Changzhou, China
Active, Not Recruiting
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
NCT02427451
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
- Locations
-
- Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
- UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
- Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
- University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
Active, Not Recruiting
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
NCT04505254
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
NCT03622788
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Anemia, +49 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
NCT04282811
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +16 more
- Locations
-
- Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione Cona, Ferrara, Italy
- Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia Alessandria, Italy
- Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto Bari, Italy
- Ao Brotzu, Presidio Ospedaliero A. Businco - Cagliari - Sc Ematologia E Ctmo Cagliari, Italy
Active, Not Recruiting
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
NCT04722172
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
- Locations
-
- Memorial Sloan Kettering Basking Ridge (All protocol activities) Basking Ridge, New Jersey, United States
- Hackensack Meridian Health (Data collection only) Hackensack, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States